CDZ173
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Common Variable Immunodeficiency (CVID), APDS / PASLI
Conditions
Common Variable Immunodeficiency (CVID), APDS / PASLI
Trial Timeline
Aug 24, 2015 → Aug 16, 2021
NCT ID
NCT02435173About CDZ173
CDZ173 is a phase 2/3 stage product being developed by Novartis for Common Variable Immunodeficiency (CVID), APDS / PASLI. The current trial status is completed. This product is registered under clinical trial identifier NCT02435173. Target conditions include Common Variable Immunodeficiency (CVID), APDS / PASLI.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02435173 | Phase 2/3 | Completed |
Competing Products
20 competing products in Common Variable Immunodeficiency (CVID), APDS / PASLI